* |
If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) |
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 362 RSUs which fully vest on 4/26/2014; 1,197 RSUs which vest in one installment of 589 on 4/25/2014 and one installment of 608 on 4/25/2015; 1,320 RSUs which vest in three installments of 435, 436 and 449 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 13,958 RSUs which fully vest on 9/1/2014 and 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
(2) |
These shares include 435 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
(3) |
These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing. |
(4) |
2,530 of these stock options are exercisable immediately and the remaining 2,530 are exercisable on 4/26/2014. |
(5) |
2,062 of these stock options are exercisable immediately and the remaining 4,188 are exercisable in two installments of 2,063 and 2,125 on 4/25/2014 and 4/25/2015, respectively. |